04/22/2026
Johns Hopkins is now offering an advanced, minimally invasive option for prostate cancer: TULSA (Transurethral Ultrasound Ablation). This MRI-guided procedure targets tumors with precision while helping preserve sexual and urinary function. We're proud to be the first in the Baltimore/D.C. region to offer this innovative treatment commercially. Learn more:
TULSA is a prostate cancer treatment that helps patients maintain quality of life with a lower risk of side effects than other treatments.